Advantages of Using Self-injection Devices to Drive Global Needle Free Injection System Market

According to our new market research study, titled "Needle-Free Injection System Market to 2028 - Global Analysis and Forecast - by Product, Technology, Type, Usability, Site of Delivery, Application, and End User," the market is expected to grow from US$ 131.64 million in 2021 to US$ 411.31 million by 2028; it is estimated to grow at a CAGR of 17.7% from 2022 to 2028. The report highlights trends prevailing in the market and drivers and restraints pertaining to the global needle free injection system market growth.

Needle free injection system is a jet injector that delivers medicine to intramuscular and subcutaneous tissue depths without needles. Major factors driving the growth of this market include the growing prevalence of chronic disease, increasing incidence of communicable disease due to needle stick injuries, advantages of drug delivery technology, and increasing demand for self-injection devices.

The use of self-injection devices is growing rapidly as the need for quicker means of delivering drugs and more standardized products over invasive drug delivery technologies is increasing. Self-injections have reduced discomfort and provide greater ease of use, which translates into better patient compliance, especially among the elderly, compared to conventional injections. Needle free injectors effectively address the volume and viscosity challenges in the case of biologics, permitting highly concentrated drugs to be diluted into larger volumes and administered over longer periods without stepping into the subcutaneous drug delivery space. Although the potential benefits of these needle free injection systems are plentiful, the most notable is the ability to self-administer high-volume, high-viscosity drugs in a non-clinical setting. Thus, the rise in demand for self-injection devices is driving the growth of the needle free injection system market.

North America holds the largest market share of the needle free injection system market, whereas Asia Pacific is expected to register the highest CAGR during the forecast period. A surge in technological advancements, increasing demand for painless and effective self-injection devices, high adoption of technologically advanced drug delivery devices, and the rising incidence of chronic diseases are driving the overall needle free injection system market in North America. Further, the US needle free injection system market is expected to grow from US$ 35.564 million in 2021 to US$ 114.47 million by 2028 at a CAGR of 18.2% during the forecast period. The growth of the market in the country is primarily driven due to rise in the development of noninvasive needle free injection system devices and the exponential rise in the infectious diseases caused due to needle stick injuries (NSIs). For instance, according to the Occupational Safety and Health Administration (OSHA), in 2020, ~5.6 million healthcare personnel in the US were at risk of work-related exposure to blood-borne pathogens via needlestick or other sharps-related injuries. Further, 44% of all NSIs are caused in operating rooms, followed by 26% in patient rooms and 8% in emergency rooms and outpatient clinics, respectively.

Moreover, rising R&D initiatives by medical device and pharma firms and regulatory grants to produce technologically advanced devices have boosted the growth of the needle free injection system market. For instance, PharmaJet, along with its partner, the Institute for Molecular Medicine (IMM), announced that the National Institute on Aging (NIA) division of the National Institutes of Health (NIH) had granted US$12 million for the clinical trials of their beta-amyloid vaccines, based on DNA and recombinant protein, for the prevention of Alzheimer's disease (AD). The phase 1 clinical study in the US began in Q2 2022, and the vaccine will be exclusively delivered by the PharmaJet Tropis Needle-free Injection System. The US government investment in needle free COVID-19 vaccines has also boosted the growth of the market. In August 2020, CNN announced that the US federal government invested ~US$ 2.5 million in efforts to create a needle free COVID-19 vaccine.

The needle free injection system market has been positively impacted by the COVID-19 pandemic, as the need for mass vaccination and self-injectable devices has been the focus since the onset of the pandemic in December 2019. As the number of cases has increased across regions, most of the major needle free injection system market players have entered into partnerships and agreements with other industry players and government agencies and have invested in R&D to develop a needle free injection system for the disease. For instance, in May 2022, Gerresheimer, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech, and cosmetics-invested in Portal Instruments, a US-based developer of a next-generation needle free drug delivery technology. Also, the increasing incidence of communicable diseases due to difficulties in vaccine storage, needlestick injuries, and needle phobia has led to high uptake and acceptance of needle free injection systems, mainly for the screening for vaccination and insulin delivery.

Crossject; INOVIO Pharmaceuticals; Zealand Pharma A/S; PharmaJet; Portal Instruments; Medical International Technologies (MIT Canada) Inc.; NuGen Medical Devices; Ferring B.V.; National Medical Products, Inc.; and Aijex Pharma International Inc. are the leading companies operating in the global needle free injection system market.

By geography, the needle free injection system market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South and Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com